magAssist

XinCheng Medical is a developer of extracorporeal artificial heart devices, focusing on the research, production, and sales of extracorporeal mid-to-short-term ventricular assist devices, also known as extracorporeal artificial hearts. Through systematic integrated design of fluid mechanics and drive mechanisms, it optimizes blood compatibility and reduces complications during use. The devices are mainly used for the treatment and recovery of patients unable to wean off cardiopulmonary bypass after open-heart surgery, as well as critical emergency conditions such as fulminant myocarditis and cardiac arrest caused by acute diseases like H1N1, severe car accidents, or drowning. Its main R&D focuses on extracorporeal life support equipment for clinical scenarios such as acute cardiogenic shock, intraoperative circulatory protection during heart surgery, and critically ill patients with organ failure. At present, its primary product lines include minimally invasive interventional artificial hearts, fully magnetically levitated extracorporeal artificial hearts, and next-generation extracorporeal membrane oxygenation systems (ECMO).